L-DOPA-induced 6-hydroxydopamine production in the striata of rodents is sensitive to the degree of denervation

Neurochemistry International

Volumn 56, Issue 2, 2010, Pages 357-362

  Borah, Anupom ^a   Mohanakumar, Kochupurackal P ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

Dopamine oxidation products; Intact nigrostriatal system; Median forebrain bundle; Monoamine oxidase inhibition; MPTP; Parkinson's disease; Reactive oxygen species; Selegiline

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CARBIDOPA PLUS LEVODOPA; LEVODOPA; OXIDOPAMINE; REACTIVE OXYGEN METABOLITE; SELEGILINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORPUS STRIATUM; DENERVATION; ELECTROCHEMICAL DETECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INNERVATION; MALE; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; ELECTROCHEMISTRY; LEVODOPA; MALE; MICE; MICE, INBRED BALB C; MPTP POISONING; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY;

MUS; RATTUS; RODENTIA;

EID: 77149128050     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2009.11.008     Document Type: Article

References (62)

1. Ando K., Maeda J., Inaji M., Okauchi T., Obayashi S., Higuchi M., Suhara T., Tanioka Y. Neurobehavioral protection by single dose l-deprenyl against MPTP-induced parkinsonism in common marmosets. Psychopharmacology (Berl.) 2008, 195:509-516.
2. Andrew R., Watson D.G., Best S.A., Midgley J.M., Wenlong H., Petty R.K. The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochem. Res. 1993, 18:1175-1177.
3. Banerjee R., Saravanan K.S., Thomas B., Sindhu K.M., Mohanakumar K.P. Evidence for hydroxyl radical scavenging action of nitric oxide donors in the protection against 1-methyl-4-phenylpyridinium-induced neurotoxicity in rats. Neurochem. Res. 2008, 33:985-995.
4. + in Sprague-Dawley rats: cellular, molecular and ultrastructural evidences. Neurochem. Res. 2007, 32:1238-1247.
5. Beal M.F. Experimental models of Parkinson's disease. Nat. Rev. Neurosci. 2001, 2:325-334.
6. Borah A., Mohanakumar K.P. Long-term l-DOPA treatment causes indiscriminate increase in dopamine levels at the cost of serotonin synthesis in discrete brain regions of rats. Cell. Mol. Neurobiol. 2007, 27:985-996.
7. Borah A., Mohanakumar K.P. Long term l-DOPA treatment causes production of 6-OHDA in the mouse striatum: involvement of hydroxyl radical. Ann. Neurosci. 2009, 16:160-165.
8. Borah A., Mohanakumar K.P. Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents. J. Pineal Res. 2009, 47:293-300.
9. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., Kopin I.J. A primate model of Parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. U.S.A. 1983, 80:4546-4550.
10. Carrillo M.C., Kanai S., Nokubo M., Ivy G.O., Sato Y., Kitani K. (-) deprenyl increases activities of superoxide dismutase and catalase in striatum but not in hippocampus: the sex and age-related differences in the optimal dose in the rat. Exp. Neurol. 1992, 116:286-294.
11. Cenci M.A. l-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment. Parkinsonism Relat. Disord. 2007, 13:S263-S267.
12. Chen L., Ding Y., Cagniard B., Van Laar A.D., Mortimer A., Chi W., Hastings T.G., Kang U.J., Zhuang X. Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J. Neurosci. 2008, 28:425-433.
13. Chiueh C.C., Miyake H., Peng M.T. Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism. Adv. Neurol. 1993, 60:251-258.
14. Chiueh C.C., Huang S.J., Murphy D.L. Suppression of hydroxyl radical formation by MAO inhibitors: a novel possible neuroprotective mechanism in dopaminergic neurotoxicity. J. Neural. Transm. Suppl. 1994, 41:189-196.
15. Cohen G., Pasik P., Cohen B., Leist A., Mytilineou C., Yahr M.D. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur. J. Pharmacol. 1984, 106:209-210.
16. Collier T.J., Steece-Collier K., McGuire S., Sortwell C.E. Cellular models to study dopaminergic injury responses. Ann. N. Y. Acad. Sci. 2003, 991:140-151.
17. Curtius H.C., Wolfensberger M., Steinmann B., Redweik U., Siegfried J. Mass fragmentography of dopamine and 6-hydroxydopamine. Application to the determination of dopamine in human brain biopsies from the caudate nucleus. J. Chromatogr. 1974, 99:529-540.
18. Filloux F., Townsend J.J. Pre- and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection. Exp. Neurol. 1993, 119:79-88.
19. Fox S.H., Chuang R., Brotchie J.M. Parkinson's disease-opportunities for novel therapeutics to reduce the problems of levodopa therapy. Prog. Brain Res. 2008, 172:479-494.
20. Gainetdinov R.R., Fumagalli F., Jones S.R., Caron M.G. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J. Neurochem. 1997, 69:1322-1325.
21. Graham D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 1978, 14:633-643.
22. Gupta A., Dawson V.L., Dawson T.M. What causes cell death in Parkinson's disease?. Ann. Neurol. 2008, 64:S3-S15.
23. Haobam R., Sindhu K.M., Chandra G., Mohanakumar K.P. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains. Behav. Brain Res. 2005, 163:159-167.
24. Hastings T.G., Lewis D.A., Zigmond M.J. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:1956-1961.
25. Heikkila R.E., Manzino L., Cabbat F.S., Duvoisin R.C. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984, 311:467-469.
26. INSA Guidelines For Care and Use of Animals in Scientific Research 2000, Indian National Science Academy Publication, New Delhi, pp. 1-26.
27. Jenner P. Functional models of Parkinson's disease: a valuable tool in the development of novel therapies. Ann. Neurol. 2008, 64:S16-S29.
28. Jenner P.G., Brin M.F. Levodopa neurotoxicity: experimental studies versus clinical relevance. Neurology 1998, 50:S39-S43.
29. Karoum F., Chrapusta S.J., Egan M.F., Wyatt R.J. Absence of 6-hydroxydopamine in the rat brain after treatment with stimulants and other dopaminergic agents: a mass fragmentographic study. J. Neurochem. 1993, 61:1369-1375.
30. Knoll J. The pharmacological basis of the beneficial effects of (-)deprenyl (selegiline) in Parkinson's and Alzheimer's diseases. J. Neural. Transm. Suppl. 1993, 40:69-91.
31. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonian in humans due to a product of meperidine-analog synthesis. Science 1983, 219:979-980.
32. Leonardi E.T., Mytilineou C. Cell culture models of neuronal degeneration and neuroprotection. Implications for Parkinson's disease. Adv. Exp. Med. Biol. 1998, 446:203-222.
33. Leret M.L., San Millan J.A., Fabre E., Gredilla R., Barja G. Deprenyl protects from MPTP-induced Parkinson-like syndrome and glutathione oxidation in rat striatum. Toxicology 2002, 170:165-171.
34. Liao P.C., Kuo Y.M., Chang Y.C., Lin C., Cherng C.F., Yu L. Striatal formation of 6-hydroxydopamine in mice treated with pargyline, pyrogallol and methamphetamine. J. Neural. Transm. 2003, 110:487-494.
35. Maharaj H., Sukhdev, Maharaj D., Scheepers M., Mokokong R., Daya S. l-DOPA administration enhances 6-hydroxydopamine generation. Brain Res. 2005, 1063:180-186.
36. Mitra N., Mohanakumar K.P., Ganguly D.K. Dissociation of serotoninergic and dopaminergic components in acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Brain Res. Bull. 1992, 28:355-364.
37. Mohanakumar K.P., Muralikrishnan D. Neurochemical mechanisms underlying neuroprotective actions of bromocriptine, salicylate, d- and l-deprenyl in neurodegeneration caused by MPTP. Neurotoxic Factors in Parkinson's Disease and Related Disorders 2000, 289-294. Kluwer Academic/Plenum Press, New York. M.A. Collins, A. Storch (Eds.).
38. Mosharov E.V., Larsen K.E., Kanter E., Phillips K.A., Wilson K., Schmitz Y., Krantz D.E., Kobayashi K., Edwards R.H., Sulzer D. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 2009, 62:218-229.
39. Muralikrishnan D., Samantaray S., Mohanakumar K.P. d-Deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity. Synapse 2003, 50:7-13.
40. Muralikrishnan D., Mohanakumar K.P. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB J. 1998, 12:905-912.
41. Napolitano A., Pezzella A., Prota G. New reaction pathways of dopamine under oxidative stress conditions: nonenzymatic iron-assisted conversion to norepinephrine and the neurotoxins 6-hydroxydopamine and 6,7-dihydroxytetrahydroisoquinoline. Chem. Res. Toxicol. 1999, 12:1090-1097.
42. Nicholas A.P., Buck K., Ferger B. Effects of levodopa on striatal monoamines in mice with levodopa-induced hyperactivity. Neurosci. Lett. 2008, 443:204-208.
43. Pandey M., Borah A., Varghese M., Barman P.K., Mohanakumar K.P., Usha R. Striatal dopamine level influences oxidative stress mediated neurodegeneration in 3-nitropropionic acid-induced Huntington's disease. Neurochem. Int. 2009, 55:431-4377.
44. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1998, Academic Press, San Diego.
45. Ramsay R.R., Singer T.P. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J. Biol. Chem. 1986, 26:7585-7587.
46. Rollema H., De Vries J.B., Westerink B.H., Van Putten F.M., Horn A.S. Failure to detect 6-hydroxydopamine in rat striatum after the dopamine releasing drugs dexamphetamine, methylamphetamine and MPTP. Eur. J. Pharmacol. 1986, 132:65-69.
47. Sairam K., Saravanan K.S., Banerjee R., Mohanakumar K.P. Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Res. 2003, 966:245-252.
48. Saravanan K.S., Sindhu K.M., Senthilkumar K.S., Mohanakumar K.P. l-Deprenyl protects against rotenone-induced, oxidative stress mediated dopaminergic neurodegeneration in rats. Neurochem. Int. 2006, 49:28-40.
49. Schapira A.H., Emre M., Jenner P., Poewe W. Levodopa in the treatment of Parkinson's disease. Eur. J. Neurol. 2009, 16:982-989.
50. Schapira A.H. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol. 2008, 7:97-109.
51. Schapira A.H. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease. Neurology 2009, 72:S44-S50.
52. Seiden L.S., Vosmer G. Formation of 6-hydroxydopamine in caudate nucleus of the rat brain after a single large dose of methyl amphetamine. Pharmacol. Biochem. Behav. 1984, 21:29-31.
53. Sikiric P., Marovic A., Matoz W., Anic T., Buljat G., Mikus D., Stancic-Rokotov D., Separovic J., Seiwerth S., Grabarevic Z., Rucman R., Petek M., Ziger T., Sebecic B., Zoricic I., Turkovic B., Aralica G., Perovic D., Duplancic B., Lovric-Bencic M., Rotkvic I., Mise S., Jagic V., Hahn V. A behavioural study of the effect of pentadecapeptide BPC 157 in Parkinson's disease models in mice and gastric lesions induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. Physiol. Paris 1999, 93:505-512.
54. + or rotenone display differential sensitivity to amphetamine and apomorphine. Pharmacol. Biochem. Behav. 2006, 84:321-329.
55. Slivka A., Cohen G. Hydroxyl radical attack on dopamine. J. Biol. Chem. 1985, 260:15466-15472.
56. Thomas B., Mohanakumar K.P. Melatonin protects against oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the mouse nigrostriatum. J. Pineal Res. 2004, 36:25-32.
57. Thomas C.E., Huber E.W., Ohlweiler D.F. Hydroxyl and peroxyl radical trapping by the monoamine oxidase-B inhibitors deprenyl and MDL 72, 974A: implications for protection of biological substrates. Free Radic. Biol. Med. 1997, 22:733-737.
58. Thomas B., Muralikrishnan D., Mohanakumar K.P. In vivo hydroxyl radical generation in the striatum following systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Brain Res. 2000, 852:221-224.
59. Toulouse A., Sullivan A.M. Progress in Parkinson's disease-where do we stand?. Prog. Neurobiol. 2008, 85:376-392.
60. Tse D.C., Mccreery R.L., Adams R.N. Potential oxidative pathways of brain catecholamines. J. Med. Chem. 1976, 19:37-40.
61. Wu R.M., Chiueh C.C., Pert A., Murphy D.L. Apparent antioxidant effect of l-deprenyl on hydroxyl radical formation and nigral injury elicited by MPP+ in vivo. Eur. J. Pharmacol. 1993, 243:241-247.
62. Youdim M.B., Bakhle Y.S. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br. J. Pharmacol. 2006, 147:S287-S296.